NASDAQ:LGVN
Longeveron Inc. Stock News
$1.75
+0.0800 (+4.79%)
At Close: Apr 26, 2024
LGVN Stock Price Increased 12.54%: Why It Happened
06:58pm, Tuesday, 30'th Mar 2021
The stock price of Longeveron Inc (NASDAQ: LGVN) increased by 12.54%. This is why it happened.
Longeveron's (LGVN) CEO Geoff Green on Q4 2020 Results - Earnings Call Transcript
12:43pm, Tuesday, 30'th Mar 2021
Longeveron's (LGVN) CEO Geoff Green on Q4 2020 Results - Earnings Call Transcript
Longeveron Provides Corporate Update and Reports Fourth Quarter and Full Year 2020 Financial Results
07:00am, Tuesday, 30'th Mar 2021
MIAMI, March 30, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and
Longeveron Schedules 2020 Fiscal Year End Business Update Conference Call
09:00am, Friday, 26'th Mar 2021
MIAMI, March 26, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and
Longeveron Inc. to Present at the Q1 Virtual Investor Summit on March 24
07:45am, Friday, 19'th Mar 2021
MIAMI, March 19, 2021 (GLOBE NEWSWIRE) -- via InvestorWire – Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chro
Longeveron Inc. Announces Partial Exercise of Over-Allotment Option in Initial Public Offering
04:30pm, Monday, 15'th Mar 2021
MIAMI, March 15, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN) ("Longeveron" or the "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related
LGVN Stock Price Increased Over 73% Intraday: Why It Happened
09:56am, Thursday, 11'th Mar 2021
The stock price of Longeveron Inc. (NASDAQ: LGVN) has increased by over 73% during intraday trading as of this morning. This is why it happened.
Trial funded in part by a Maryland Stem Cell Research Fund TEDCO Grant Trial funded in part by a Maryland Stem Cell Research Fund TEDCO Grant
Longeveron Announces Successful Completion of Phase 2b Clinical Study of Lomecel-B Infusion to Treat Aging Frailty
08:30am, Wednesday, 03'rd Mar 2021
Trial funded in part by a National Institute on Aging Small Business Innovation Research (SBIR) Grant
Longeveron's Allogeneic Cell Therapy Completes Early-Stage Study In Congenital Heart Defect
01:44pm, Wednesday, 24'th Feb 2021
Longeveron Inc (NASDAQ: LGVN) completes Phase 1 study of Lomecel-B in Hypoplastic Left Heart Syndrome (HLHS). Full results from the study will be released in Q2 2021.
CEO of Longeveron Inc. to Present at the Intercontinental Summit on Aging & Gerontology
08:30am, Friday, 19'th Feb 2021
MIAMI, Feb. 19, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and
MIAMI, Feb. 18, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and
U.S. IPO Weekly Recap: IPO Frenzy Brings The Year's Largest Deal And Biggest Pop In A 17 IPO Week
11:23pm, Sunday, 14'th Feb 2021
The IPO frenzy continued this past week as 17 IPOs and 26 SPACs entered the public market. Headlining the week were dating app Bumble, which completed the year's largest deal so far, and Chinese cloud
Longeveron Inc. Announces Pricing of an Upsized $26.6 Million Initial Public Offering and Nasdaq Listing
10:27pm, Thursday, 11'th Feb 2021
MIAMI, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and l
